Development of new regenerative medicine technology for implantation of artificial dermis using regeneration-promoting drugs that promote cell engraftment.

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08651
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Tokai University
• Principal Investigator: SUMIYOSHI Hideaki 東海大学, 医学部, 准教授 (60343357)
• Co-Investigator(Kenkyū-buntansha): 岡村 陽介 東海大学, 工学部, 教授 (40365408) ; 遠藤 整 東海大学, 医学部, 准教授 (10550551) ; 根本 仁 東海大学, 医学部, 講師 (40465183)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 表皮伸長促進 / 創薬 / 新型人工真皮 / 再生医療 / 臨床応用

Outline of Final Research Achievements

The purpose of this project is to reach the level of clinical application of the re-epithelialization-promoting component derived from Moon jellyfish. Therefore, ① Purification of medicinal ingredients derived from Moon jellyfish. ② Development of next-generation artificial dermis. ③ Promotion of artificial dermal regeneration medical technology, including medication. We conducted the above three studies. In ①, we obtained a low-molecular-weight peptides that have re-epithelialization-promoting activity despite being a mixture and have no biological toxicity. In ②, we developed a novel artificial dermis that has excellent long-term engraftment and the ability to reproduce natural tissue. In ③, we developed a sustained-release carrier from drug wrapping technology using nanosheet technology, and constructed a regenerative medicine model that combines medication and artificial dermis. The next challenge is technology transfer for use in human medicine.

Free Research Field

再生医療

Academic Significance and Societal Importance of the Research Achievements

ミズクラゲ成分の細胞遊走促進作用は申請者による独自の発見である。人工物上に直接上皮を誘引できる薬剤は他に無く、薬効成分を同定できれば画期的な新薬となり得る。現在主流の幹細胞を用いる再生医療はコストと安全性に課題があるが、人工構造体を用いた再生医療は安価で、経過さえ良ければ社会的にも受け入れ易い再生医療となる。難治性皮膚潰瘍や褥瘡など再生能力の衰えた患者に対しての人工真皮を用いる治療は、適用が難しい事例であるが、細胞を効率的に動員し組織を再構成する技術によって適用範囲を拡げることも可能となる。高齢化と飽食化で増加するこれらの疾患に対応し、健康寿命の延長と医療費の削減の両面に波及効果を見込める。